Advanced colon cancer: Antiprogressive immunotherapy using an autologous hemoderivative

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 91-104

  Lasalvia Prisco, Eduardo ^a,d   Garcia Giralt, Emilio ^b   Cucchi, Silvia ^c   Vázquez, Jesús ^c,d   Lasalvia Galante, Eduardo ^c   Golomar, Wilson ^c,d   Larrañaga, Joshemaria ^c,d  

^a PharmaBlood Inc   (United States)

^b Centre De Cancerologie Hartmann   (France)

^c Interdoctors   (Uruguay)

^d National Institute of Oncology   (Uruguay)

Author keywords

Autologous hemoderivative; Colon cancer; Vaccine

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSAY; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE; THERMOSTABILITY; TUMOR GROWTH;

AGED; COLONIC NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY;

EID: 33646885489     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:91     Document Type: Article

References (19)

1. Lasalvia E, et al. Autologous induction of tumoral fibrogenesis. Neoplasia 1995; 12:5-10.
2. Lasalvia E, Cucchi S, Carlevaro T, Vasquez J, Riotorto R, Fierro L. Anti-metastatic effect of a blood fraction from cancer patients (Meeting abstract). Proceedings 31st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 1995, Abstract No. 730
3. Lasalvia-Prisco E, et al. Antitumoral effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther 2003; 2:155-160.
4. Berd D, Mastrangelo MJ, Engstrong P, Maguire H. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42:4862-4866.
5. Leong SP, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999; 22:166.
6. Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
7. Therasse P, et al. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Nat Cancer Inst 2000; 92:205-216.
8. World Medical Association Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised in Tokyo, 1975, in Venice, 1983, in Hong Kong, 1989. Version with changes of 1997.
9. PDQ (Physician Data Query) National Cancer Institute, comprehensive cancer database.
10. Ozer H, et al. 2000 update of recommendations for the use of heamatopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol, 2000; 18:3558-3585.
11. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S, Vazquez J, Lasalvia-Galante E, Golomar W. Colorectal cancer: comparative effects of an autologous hemoderivative vaccine with a CEA vaccine and/or an autologous [CD4+CD25+] vaccine. Proceedings 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, 2005, Abstract No. 2596.
12. Wan Fai Ng, et al. Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 2001; 98:2736-2744.
13. Gauthier LR, et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001; 84:631-635.
14. National Cancer Institute, US: Common terminology criteria for adverse events v3.0 (CTCAE).
15. Saetang T, Suttijitpaisal P, Ratanabanangkoon K. Preparations of toxic components from Naja kaouthia venom by selective heat denaturation. J Nat Toxins 1998; 7:37-44.
16. Bruster HTH, Kuntz BME, Scheja JW. Autovaccination plus heat-inactivated autologous plasma in AIDS Patients. Lancet 1988; 1:1284-1285.
17. Petrunin DD, Lopukin Iu M, Molodenkov MN, Olifirenko GA. Immunochemical identification of thermostable alpha-glycoprotein in blood sera in various immune system diseases. Biull Eksp Biol Med 1982; 93:66-68.
18. Snegotska O. [Autovaccines for the treatment of cancer]. Folia Clin Int (Barc. Spain). 1965; 15: 303-308.
19. Liyanage UK, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761.